News

Article

R+D Custom Automation Supplies Vial Machinery to SiO2 Materials Science

The agreement will accelerate production of SiO2’s plastic vials for vaccines and therapeutics for Operation Warp Speed.

R+D Custom Automation, a privately-owned United States provider of automation systems, has announced an agreement with SiO2 Materials Science to supply machinery for producing SiO2’s plastic vials for storing SARS-CoV-2 vaccines and therapeutics, R+D Custom Automation announced in a July 9, 2020 press release. SiO2 was recently awarded a $143 million contract with the federal government as part of the Operation Warp Speed initiative to produce its patented plastic vials that incorporate a glass-like barrier. The contract aims for capacity to produce 40 million vials in June, 80 million in September, and 120 million in November 2020.

"We are honored to develop and manufacture the automation machinery required to produce the vials that are essential to the COVID-19 vaccine clinical trials and production," stated Loren Esch, CEO, R+D Custom Automation, in the press release. "R+D Custom Automation has been able to respond quickly, outsourcing as needed to meet machine deadlines in an accelerated timeframe. Thanks to our dedicated employees who are working long hours and weekends, what may have taken most companies eighteen months to execute, we've accomplished in a fraction of the time."

Source: R+D Custom Automation

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content